2026-08-29T14:12:15Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/125632024-09-27T08:41:00Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Sánchez-Alonso, Santiago author Setti-Jerez, Giulia author Arroyo, Montserrat author Hernández, Tathiana author Martos, Mª Inmaculada author Sánchez-Torres, Jose Miguel author Colomer, Ramon author Ramiro, Almudena R author Alfranca, Arantzazu author 2020-09-10 Lung cancer is one of the most frequent malignancies in humans and is a major cause of death. A number of therapies aimed at reinforcing antitumor immune response, including antiprogrammed cell death protein 1 (anti-PD-1) antibodies, are successfully used to treat several neoplasias as non-small cell lung cancer (NSCLC). However, host immune mechanisms that participate in response to anti-PD-1 therapy are not completely understood. We used a syngeneic immunocompetent mouse model of NSCLC to analyze host immune response to anti-PD-1 treatment in secondary lymphoid organs, peripheral blood and tumors, by flow cytometry, immunohistochemistry and quantitative real-time PCR (qRT-PCR). In addition, we also studied specific characteristics of selected immune subpopulations in ex vivo functional assays. We show that anti-PD-1 therapy induces a population of circulating T follicular helper cells (cTfh) with enhanced B activation capacity, which participates in tumor response to treatment. Anti-PD-1 increases the number of tertiary lymphoid structures (TLS), which correlates with impaired tumor growth. Of note, TLS support cTfh-associated local antibody production, which participates in host immune response against tumor. These findings unveil a novel mechanism of action for anti-PD-1 therapy and provide new targets for optimization of current therapies against lung cancer. J Immunother Cancer. 2020; 8(2):e001187 10.1136/jitc-2020-001187 2051-1426 Journal for immunotherapy of cancer 32900863 http://hdl.handle.net/20.500.12105/12563 A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy.